Cargando…

Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies

A hallmark of patients with autoimmune polyendocrine syndrome type 1 (APS-1) is serological neutralizing autoantibodies against type 1 interferons (IFN-I). The presence of these antibodies has been associated with severe course of COVID-19. The aims of this study were to investigate SARS-CoV-2 vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolff, Anette S.B., Hansen, Lena, Grytaas, Marianne Aa., Oftedal, Bergithe E., Breivik, Lars, Zhou, Fan, Hufthammer, Karl Ove, Sjøgren, Thea, Olofsson, Jan Stefan, Trieu, Mai Chi, Meager, Anthony, Jørgensen, Anders P., Lima, Kari, Greve-Isdahl Mohn, Kristin, Langeland, Nina, Cox, Rebecca Jane, Husebye, Eystein S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251722/
https://www.ncbi.nlm.nih.gov/pubmed/37346050
http://dx.doi.org/10.1016/j.isci.2023.107084
_version_ 1785056003305242624
author Wolff, Anette S.B.
Hansen, Lena
Grytaas, Marianne Aa.
Oftedal, Bergithe E.
Breivik, Lars
Zhou, Fan
Hufthammer, Karl Ove
Sjøgren, Thea
Olofsson, Jan Stefan
Trieu, Mai Chi
Meager, Anthony
Jørgensen, Anders P.
Lima, Kari
Greve-Isdahl Mohn, Kristin
Langeland, Nina
Cox, Rebecca Jane
Husebye, Eystein S.
author_facet Wolff, Anette S.B.
Hansen, Lena
Grytaas, Marianne Aa.
Oftedal, Bergithe E.
Breivik, Lars
Zhou, Fan
Hufthammer, Karl Ove
Sjøgren, Thea
Olofsson, Jan Stefan
Trieu, Mai Chi
Meager, Anthony
Jørgensen, Anders P.
Lima, Kari
Greve-Isdahl Mohn, Kristin
Langeland, Nina
Cox, Rebecca Jane
Husebye, Eystein S.
author_sort Wolff, Anette S.B.
collection PubMed
description A hallmark of patients with autoimmune polyendocrine syndrome type 1 (APS-1) is serological neutralizing autoantibodies against type 1 interferons (IFN-I). The presence of these antibodies has been associated with severe course of COVID-19. The aims of this study were to investigate SARS-CoV-2 vaccine tolerability and immune responses in a large cohort of patients with APS-1 (N = 33) and how these vaccinated patients coped with subsequent infections. We report that adult patients with APS-1 were able to mount adequate SARS-CoV-2 spike-specific antibody responses after vaccination and observed no signs of decreased tolerability. Compared with age- and gender-matched healthy controls, patients with APS-1 had considerably lower peak antibody responses resembling elderly persons, but antibody decline was more rapid in the elderly. We demonstrate that vaccination protected patients with APS-1 from severe illness when infected with SARS-CoV-2 virus, overriding the systemic danger of IFN-I autoantibodies observed in previous studies.
format Online
Article
Text
id pubmed-10251722
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-102517222023-06-09 Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies Wolff, Anette S.B. Hansen, Lena Grytaas, Marianne Aa. Oftedal, Bergithe E. Breivik, Lars Zhou, Fan Hufthammer, Karl Ove Sjøgren, Thea Olofsson, Jan Stefan Trieu, Mai Chi Meager, Anthony Jørgensen, Anders P. Lima, Kari Greve-Isdahl Mohn, Kristin Langeland, Nina Cox, Rebecca Jane Husebye, Eystein S. iScience Article A hallmark of patients with autoimmune polyendocrine syndrome type 1 (APS-1) is serological neutralizing autoantibodies against type 1 interferons (IFN-I). The presence of these antibodies has been associated with severe course of COVID-19. The aims of this study were to investigate SARS-CoV-2 vaccine tolerability and immune responses in a large cohort of patients with APS-1 (N = 33) and how these vaccinated patients coped with subsequent infections. We report that adult patients with APS-1 were able to mount adequate SARS-CoV-2 spike-specific antibody responses after vaccination and observed no signs of decreased tolerability. Compared with age- and gender-matched healthy controls, patients with APS-1 had considerably lower peak antibody responses resembling elderly persons, but antibody decline was more rapid in the elderly. We demonstrate that vaccination protected patients with APS-1 from severe illness when infected with SARS-CoV-2 virus, overriding the systemic danger of IFN-I autoantibodies observed in previous studies. Elsevier 2023-06-09 /pmc/articles/PMC10251722/ /pubmed/37346050 http://dx.doi.org/10.1016/j.isci.2023.107084 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wolff, Anette S.B.
Hansen, Lena
Grytaas, Marianne Aa.
Oftedal, Bergithe E.
Breivik, Lars
Zhou, Fan
Hufthammer, Karl Ove
Sjøgren, Thea
Olofsson, Jan Stefan
Trieu, Mai Chi
Meager, Anthony
Jørgensen, Anders P.
Lima, Kari
Greve-Isdahl Mohn, Kristin
Langeland, Nina
Cox, Rebecca Jane
Husebye, Eystein S.
Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
title Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
title_full Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
title_fullStr Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
title_full_unstemmed Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
title_short Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
title_sort vaccination prevents severe covid-19 outcome in patients with neutralizing type 1 interferon autoantibodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251722/
https://www.ncbi.nlm.nih.gov/pubmed/37346050
http://dx.doi.org/10.1016/j.isci.2023.107084
work_keys_str_mv AT wolffanettesb vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT hansenlena vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT grytaasmarianneaa vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT oftedalbergithee vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT breiviklars vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT zhoufan vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT hufthammerkarlove vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT sjøgrenthea vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT olofssonjanstefan vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT trieumaichi vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT meageranthony vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT jørgensenandersp vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT limakari vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT greveisdahlmohnkristin vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT langelandnina vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT coxrebeccajane vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies
AT husebyeeysteins vaccinationpreventsseverecovid19outcomeinpatientswithneutralizingtype1interferonautoantibodies